Arcus Biosciences RCUS Other Current Liabilities
Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherSundryLiabilitiesCurrent.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Arcus Biosciences's other current liabilities?
- Arcus Biosciences (RCUS) reported other current liabilities of $10M in Q1 2026.
- How has Arcus Biosciences's other current liabilities changed year-over-year?
- Arcus Biosciences's other current liabilities decreased by 41.2% year-over-year, from $17M to $10M.
- What is the long-term trend for Arcus Biosciences's other current liabilities?
- Over 3 years (2022 to 2025), Arcus Biosciences's other current liabilities has grown at a 81.7% compound annual growth rate (CAGR), from $3M to $18M.
- What does other current liabilities mean?
- Miscellaneous current obligations not classified in specific categories — a catch-all for short-term liabilities.